Trial Profile
A Randomized, Double-Blind, Placebo-Controlled, Multiple-Dose, Phase 2 Dose-Ranging Study to Evaluate the Efficacy and Safety of 17 Weeks of Weekly Injections of CJC-1134-PC in Patients With Type 2 Diabetes Mellitus on Metformin Monotherapy.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 17 Sep 2021
Price :
$35
*
At a glance
- Drugs Albenatide (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics; Therapeutic Use
- 09 Mar 2012 Actual patient number is 74 as reported by ClinicalTrials.gov.
- 09 Mar 2012 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 19 Jan 2012 Lead trial investigator sidentified as reported by ClinicalTrials.gov.